-
HD2026 Milton Wexler Biennial Symposium Day 3
Latest News
-
HD2026 Milton Wexler Biennial Symposium Day 2
⏱️ 23 min read | Day 2 of #HD2026 brought us updates on the mechanics of somatic instability, new ways to track HD in people, AI tools to help drive research forward, and developments in our understanding of the HTT protein. Catch up right here.
-
Memantine in HD: dose is everything
Memantine, a drug already used in Alzheimer’s disease, might help in HD, but a mouse study shows dose is everything.
-
An active lifestyle may make a difference to HD symptoms
More reasons to be active: a passive lifestyle may contribute to earlier onset of symptoms in HD.
-
Frequently asked questions, January 2011
Answers to frequently-asked questions about HD – the first in a regular series of HDBuzz FAQ articles.
-
Getting the data out – a new scientific journal just for HD
New scientific journal PLoS Currents HD promises rapid publication & open access, improving scientific communication
-
Dimebon: disappointing in Alzheimer’s but might work in HD
Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
-
Does HD cause brains to develop differently?
Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
-
Is Huntington’s disease twice as common as we thought?
New data suggest there may be twice as many people with HD symptoms as previously thought – and even more at risk
-
Two large HD observational studies – COHORT and Registry – merge to create ENROLL-HD
Merger of two major Huntington’s Disease observational trials creates ENROLL-HD
-
Huntexil for symptoms of Huntington's disease: where are we now?
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
-
Minocycline: the end of the road?
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Show 9 more Show less
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
